These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 15086644)

  • 1. Efficacy and safety of rofecoxib 12.5 mg versus nabumetone 1,000 mg in patients with osteoarthritis of the knee: a randomized controlled trial.
    Kivitz AJ; Greenwald MW; Cohen SB; Polis AB; Najarian DK; Dixon ME; Moidel RA; Green JA; Baraf HS; Petruschke RA; Matsumoto AK; Geba GP;
    J Am Geriatr Soc; 2004 May; 52(5):666-74. PubMed ID: 15086644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of patients with osteoarthritis with rofecoxib compared with nabumetone.
    Weaver AL; Messner RP; Storms WW; Polis AB; Najarian DK; Petruschke RA; Geba GP; Tershakovec AM
    J Clin Rheumatol; 2006 Feb; 12(1):17-25. PubMed ID: 16484875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gastrointestinal medications and procedures in osteoarthritis patients treated with rofecoxib compared with nonselective NSAIDs.
    Watson DJ; Harper SE; Zhao PL; Bolognese JA; Simon TJ
    MedGenMed; 2001 Nov; 3(4):6. PubMed ID: 11965201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs.
    Langman MJ; Jensen DM; Watson DJ; Harper SE; Zhao PL; Quan H; Bolognese JA; Simon TJ
    JAMA; 1999 Nov; 282(20):1929-33. PubMed ID: 10580458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter, randomized, controlled trial to evaluate the safety profile, tolerability, and efficacy of rofecoxib in advanced elderly patients with osteoarthritis.
    Truitt KE; Sperling RS; Ettinger WH; Greenwald M; DeTora L; Zeng Q; Bolognese J; Ehrich E;
    Aging (Milano); 2001 Apr; 13(2):112-21. PubMed ID: 11405384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pain management in osteoarthritis: a focus on onset of efficacy--a comparison of rofecoxib, celecoxib, acetaminophen, and nabumetone across four clinical trials.
    Battisti WP; Katz NP; Weaver AL; Matsumoto AK; Kivitz AJ; Polis AB; Geba GP
    J Pain; 2004 Nov; 5(9):511-20. PubMed ID: 15556830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of rofecoxib, celecoxib, and acetaminophen in patients with osteoarthritis of the knee. A combined analysis of the VACT studies.
    Schnitzer TJ; Weaver AL; Polis AB; Petruschke RA; Geba GP;
    J Rheumatol; 2005 Jun; 32(6):1093-105. PubMed ID: 15940774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial.
    Geba GP; Weaver AL; Polis AB; Dixon ME; Schnitzer TJ;
    JAMA; 2002 Jan; 287(1):64-71. PubMed ID: 11754710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebo controlled pilot study of rofecoxib. Rofecoxib Osteoarthritis Pilot Study Group.
    Ehrich EW; Schnitzer TJ; McIlwain H; Levy R; Wolfe F; Weisman M; Zeng Q; Morrison B; Bolognese J; Seidenberg B; Gertz BJ
    J Rheumatol; 1999 Nov; 26(11):2438-47. PubMed ID: 10555907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of adverse renovascular experiences among osteoarthritis patients treated with rofecoxib and comparator non-selective non-steroidal anti-inflammatory agents.
    Gertz BJ; Krupa D; Bolognese JA; Sperling RS; Reicin A
    Curr Med Res Opin; 2002; 18(2):82-91. PubMed ID: 12017215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of rofecoxib in patients with chronic low back pain: results from two 4-week, randomized, placebo-controlled, parallel-group, double-blind trials.
    Katz N; Ju WD; Krupa DA; Sperling RS; Bozalis Rodgers D; Gertz BJ; Gimbel J; Coleman S; Fisher C; Nabizadeh S; Borenstein D;
    Spine (Phila Pa 1976); 2003 May; 28(9):851-8; discussion 859. PubMed ID: 12941996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Rofecoxib/Ibuprofen Comparator Study Group.
    Day R; Morrison B; Luza A; Castaneda O; Strusberg A; Nahir M; Helgetveit KB; Kress B; Daniels B; Bolognese J; Krupa D; Seidenberg B; Ehrich E
    Arch Intern Med; 2000 Jun; 160(12):1781-7. PubMed ID: 10871971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rofecoxib 12.5 mg, rofecoxib 25 mg, and celecoxib 200 mg in the treatment of symptomatic osteoarthritis: results of two similarly designed studies.
    Smugar SS; Schnitzer TJ; Weaver AL; Rubin BR; Polis AB; Tershakovec AM
    Curr Med Res Opin; 2006 Jul; 22(7):1353-67. PubMed ID: 16834834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib Phase III Protocol 035 Study Group.
    Cannon GW; Caldwell JR; Holt P; McLean B; Seidenberg B; Bolognese J; Ehrich E; Mukhopadhyay S; Daniels B
    Arthritis Rheum; 2000 May; 43(5):978-87. PubMed ID: 10817549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone).
    Reicin AS; Shapiro D; Sperling RS; Barr E; Yu Q
    Am J Cardiol; 2002 Jan; 89(2):204-9. PubMed ID: 11792343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of rofecoxib 12.5 mg and celecoxib 200 mg in two similarly designed osteoarthritis studies.
    Birbara C; Ruoff G; Sheldon E; Valenzuela C; Rodgers A; Petruschke RA; Chang DJ; Tershakovec AM
    Curr Med Res Opin; 2006 Jan; 22(1):199-210. PubMed ID: 16393445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health-related quality-of-life effects of oxaprozin and nabumetone in patients with osteoarthritis of the knee.
    Zhao SZ; Dedhiya SD; Bocanegra TS; Fort JG; Kuss ME; Rush SM
    Clin Ther; 1999 Jan; 21(1):205-17. PubMed ID: 10090436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the efficacy and safety of oxaprozin and nabumetone in the treatment of patients with osteoarthritis of the knee.
    Weaver A; Rubin B; Caldwell J; McMahon FG; Lee D; Makarowski W; Offenberg H; Sack M; Sikes D; Trapp R
    Clin Ther; 1995; 17(4):735-45. PubMed ID: 8565037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the COX-inhibiting nitric oxide donator AZD3582 and rofecoxib in treating the signs and symptoms of Osteoarthritis of the knee.
    Schnitzer TJ; Kivitz AJ; Lipetz RS; Sanders N; Hee A
    Arthritis Rheum; 2005 Dec; 53(6):827-37. PubMed ID: 16342089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A double-masked comparison of Naprelan and nabumetone in osteoarthritis of the knee. Naprelan Study Group.
    Fleischmann RM; Flint K; Constantine G; Kolecki B
    Clin Ther; 1997; 19(4):642-55. PubMed ID: 9377610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.